This show about a kid who can't outrun hijinks and circumstances has optimism, resilience, and strong friendships at its core ...

Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the FDA. Enhertu, a HER2-directed antibody-drug conjugate, inhibits tumor ...

For a limited time, fans can now represent their enthusiastic passion for the Rams and the city of Los Angeles with the “LA Bold” collection, a new stylish clothing line packed with West Coast flavor ...

After more than a year of early access, the long-awaited (and already acclaimed) Hades II—a sequel to the Greek myth-themed roguelite from Supergiant Games—finally announced its release date with a ...

It can look different and feel different, but it is only different if, in fact, it actually is different. Soon enough, all the good, positive vibes mustered by the Giants about their offensive line ...

MINNEAPOLIS — When starting left tackle Cam Robinson went down with a leg injury on the first day of training camp practices at the Greenbrier last week, there was major concern about how the ...

ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose, improves insulin sensitivity, and causes weight loss by ...

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy). Data from the phase III ASCENT-03 study ...

Orforglipron, Eli Lilly’s investigational oral glucagon-like peptide 1 receptor agonist (GLP-1 RA), achieved positive phase 3 results for both A1c and weight loss, according to top-line data released ...